Skip To Main Content
Jacquelyn M Lykken on Muck Rack

Jacquelyn M Lykken

As seen in: The Journal of Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jacquelyn M

Contact Jacquelyn M, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Lymphoma Galectin-1 Expression Drives CD20 Immunotherapy Resistance

|
By Jacquelyn M Lykken, Masahiro Kamata, Mayuka Horikawa, Veronique Minard-Colin, Tomomitsu Miyagaki
| The Journal of Immunology Verified
Non-Hodgkin’s lymphoma is the most commonly diagnosed hematologic cancer of adults in the United States, with the vast majority deriving from malignant B lymphocytes that express cell surface CD20. CD20 immunotherapy (Rituximab) is widely used to treat Non-Hodgkin’s lymphoma, even though the initial effectiveness of Rituximab varies widely amongst patients and typically wanes over time.
Open in Who Shared Issue with article?

Regulatory B10 cells control immune responses via antigen-specific pathways

|
By Kathleen Candando, Masahiro Kamata, Evgueni Kountikov, Jacquelyn M Lykken, Ayumi Yoshizaki
| The Journal of Immunology Verified
B cells secrete antigen-specific antibodies during immune responses to neutralize pathogens and other threats. Despite this well-characterized pro-inflammatory B cell function, a rare subset of B cells (B10 cells) in both humans and mice are known to produce the inhibitory cytokine interleukin 10 (IL-10) and provide negative regulation of inflammation and T cell-dependent autoimmunity.
Open in Who Shared Issue with article?
See all 2 articles